Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →GEN reported Halozyme inked $2B+ in combined ENHANZE deals with BMS and Roche on the same day, with Halozyme more than doubling its 2017 revenue guidance to…
AJMC reported FDA approval of Opdivo Qvantig as the first and only SC PD-1 inhibitor in December 2024, validating the original 2017 BMS-Halozyme thesis with a…
FiercePharma noted BMS scored an SC Opdivo win against Merck's Keytruda timeline, extending Opdivo lifecycle as biosimilar and IRA pressure mounts on IV…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
BMS and Halozyme entered a global collaboration and license agreement for the ENHANZE subcutaneous drug delivery platform applied to up to 11 BMS immuno-oncology targets including PD-1. Halozyme received $105M upfront plus up to $160M in milestones per nominated target (~$1.76B aggregate if all 11 advance) plus additional combination-product milestones plus tiered royalties.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Halozyme Therapeutics, Inc. (this deal) | 2017 | $1.9B | — |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2017 deals · Bristol-Myers Squibb Company deals · Oncology deals